1. Home
  2. TIRX vs AKTX Comparison

TIRX vs AKTX Comparison

Compare TIRX & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TIAN RUIXIANG Holdings Ltd

TIRX

TIAN RUIXIANG Holdings Ltd

HOLD

Current Price

$0.47

Market Cap

13.5M

Sector

Finance

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.26

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TIRX
AKTX
Founded
2010
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.5M
14.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TIRX
AKTX
Price
$0.47
$0.26
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$3.30
AVG Volume (30 Days)
200.6K
2.3M
Earning Date
08-22-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
158.74
N/A
52 Week Low
$0.42
$0.22
52 Week High
$6.45
$1.73

Technical Indicators

Market Signals
Indicator
TIRX
AKTX
Relative Strength Index (RSI) 26.91 31.13
Support Level $0.47 $0.22
Resistance Level $1.10 $0.47
Average True Range (ATR) 0.13 0.07
MACD -0.02 -0.00
Stochastic Oscillator 5.70 11.07

Price Performance

Historical Comparison
TIRX
AKTX

About TIRX TIAN RUIXIANG Holdings Ltd

Tian Ruixiang Holdings Ltd is an Insurance Brokerage firm. It distributes a wide range of insurance products, which are categorized into two groups; property and casualty insurance, such as commercial property insurance, liability insurance, accidental insurance, and automobile insurance; and other insurances, such as health insurance, life insurance, and miscellaneous insurances. It also generates a small amount of revenue from risk management services. The firm act on behalf of its customers seeking insurance coverage from insurance companies. It generates revenue from the provision of insurance brokerage services.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: